The Los Angeles Times recently reported that the Center for Science in the Public Interest (CSPI) is planning to sue fast-food giant McDonald's if the company does not comply with its demands to remove toys from "Happy Meals". CSPI claims that marketing unhealthy food with toys is contributing to the childhood obesity epidemic and should be stopped immediately.

The announcement by CSPI comes just weeks after a California county banned not only toys but all other promotions aimed at children that involve McDonald's Happy Meals. By doing this, the county believes that children will be less attracted to fatty foods that are high in salt and calories.

According to the same article, back in April, Santa Clara County, California, also banned toy promotions from fast food meals sold in unincorporated parts of the county.

Spokesmen from McDonald's denied that Happy Meals are inherently unhealthy, citing the fact that the meals are of an appropriate size and that children have the option to swap out the fries and soda for apples and juice. They also explained that giving away toys with children's meals is part of the fun of a family dining experience.

Since 2008 when apples were first introduced as an option in Happy Meals, customers have ordered them more than 100 million times, illustrating that when given healthier options, customers often choose them for their children instead. Read more...
Cold symptoms

The abbreviation KPU stands for pyrroluria, which is a frequently disregarded metabolic disorder that may cause numerous unspecific symptoms. However, it is comparatively easy to treat. In general, KPU (a.k.a. pyrroluria, malvaria, or HPU) is a genetically determined anomaly of hemal production (an aspect of blood formation) which causes increased hemal pyrrole concentrations.

Normally, this substance does not circulate freely in the blood but is bound by bile acid and excreted through the intestines. In KPU-cases, however, crypto pyrrole is increasingly excreted in the urine – unfortunately along with vitamin B6, zinc, and manganese which the body lacks due to this process.
In combination with increased stress (e.g. acute viral rhinopharyngitis, burns, injuries/accidents, intestinal infections, or psychic stress) this causes a wide range of symptoms, such as:
disturbances of memory and sleep, erratic mood swings, depression, hair loss, proneness to infections, and chapped skin. There is also a possible relation to ADHD with children and juveniles. Read more...
Immunice for Immune Support

(HealthDay News) -- The needle pricks involved in acupuncture may help relieve pain by triggering a natural painkilling chemical called adenosine, a new study has found.

The researchers also believe they can enhance acupuncture's effectiveness by coupling the process with a well-known cancer drug -- deoxycoformycin -- that maintains adenosine levels longer than usual.

"Acupuncture has been a mainstay of medical treatment in certain parts of the world for 4,000 years, but because it has not been understood completely, many people have remained skeptical," lead author Dr. Maiken Nedergaard, co-director of the Center for Translational Neuromedicine at the University of Rochester Medical Center, said in a news release. "In this work, we provide information about one physical mechanism through which acupuncture reduces pain in the body." Read more...

Joint Mender for Joint Care

Neurological and Immune Reactive Conditions Affecting Kids: The mercury connection to neurological pervasive developmental disorders(autism, schizophrenia, dyslexia, ADD,childhood depression, learning disabilities, OCD, etc.)and developmental immune conditions (eczema, asthma, and allergies)Bernard Windham- Chemical Engineer

http://www.home.earthlink.net/~berniew1/kidshg.html

The incidence of neurotoxic, allergic, and immune reactive conditions such as autism, schizophrenia, ADD, dyslexia, allergies, asthma, eczema, psoriasis, childhood diabetes, etc. have been increasing rapidly in recent years. A recent report by the National Research Council found that 50% of all pregnancies in the U.S. are now resulting in prenatal or postnatal mortality, significant birth defects, developmental disabilities or otherwise chronically unhealthy babies(3). Read more...

Immunice for Immune Support

What is tagatose? I heard it mentioned as a sugar substitute, but it's a new one on me. Is it safe or just another sweetener we should avoid? And what's the latest word on the safety of Splenda?

Tagatose is a natural sweetener that is 92 percent as sweet as sugar, but has only one-third of the calories. The FDA approved its use in foods and beverages in 2001. You'll see it in packaged cereals and diet sodas, and it is also used in mouthwash, toothpaste, lipstick and in various drugs, both prescription and over-the-counter. Read more...

Ayurtox for Body Detoxification

Findings reported in article published online on May 6, 2010 in the Proceedings of the National Academy of Sciences (http://www.pnas.org/) suggest that vinpocetine, a derivative of vincamine (from the periwinkle plant), could be useful for the treatment of chronic inflammatory diseases such as atherosclerosis, chronic obstructive pulmonary disease (COPD), arthritis, infectious diseases and cancer. Vinpocetine is a dietary supplement that has been used for many years to help prevent cerebrovascular disorders and memory loss, however, the compound's potential benefit in other disorders has not been explored.Read more...

ClariMind Memory & Concentration Supplement

Melanoma-initiating cells identified by study by Krista Conger, News release, Stanford School of Medicine, June 30, 2010. Excerpt:

Scientists at the School of Medicine have identified a cancer-initiating cell in human melanomas. The finding is significant because the existence of such a cell in the aggressive skin cancer has been a source of debate. It may also explain why current immunotherapies are largely unsuccessful in preventing disease recurrence in human patients.

The news release is about this publication: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 by Alexander D Boiko and 11 co-authors, including Irving L. Weissman, Nature 2010(Jul 1); 466(7302): 133-7. [FriendFeed entry].

A blog post about this same publication is: Stanford scientists identify a melanoma-initiating cell by Krista Conger, Scope blog, Stanford School of Medicine, June 20, 2010.

See also a commentary about the publication: Cancer stem cells: Invitation to a second round by Peter Dirks, Nature 2010(Jul 1); 466(7302): 40-1. Excerpt:

Boiko et al. study a type of human skin cancer called melanoma and, in particular, cancer cells enriched in a stem-cell marker called CD271. They find that, unlike other cells from the same tumour, CD271-expressing (CD271+) cells could initiate and maintain tumour growth in vivo — an observation consistent with the existence of a melanoma-cell functional hierarchy.

This finding reflects a view different from that of an earlier study by Quintana et al.[3], which demonstrated that, in some cases, as many as 50% of human melanoma cells have tumorigenic potential. In addition, no marker tested identified a tumorigenic subpopulation. The authors[3] concluded that the frequency of cancer cells that can initiate tumorigenesis depends, in part, on the assessment techniques and assays.

Another news item, based on the same publication, is: New hope in fight against skin cancer as deadly 'master cells' are identified for first time, Mail Online, July 1, 2010. Excerpt:

However Dr Alexander Boiko, who made the discovery at Stanford University, said the newly discovered 'stem cells' in advanced skin cancers were often missed by conventional immunotherapy.

'Without wiping out the cells at the root of the cancer, the treatment will fail,' he said.

Comments: Boiko et al. and Dirks suggest reasons why results different from those of Quintana et al. were obtained. One possibility is that the melanomas that the latter authors studied were at an advanced stage. If, as a cancer progresses, more cells acquire the attributes of cancer stem cells, then advanced melanomas may contain very high frequencies of tumorigenic cells.

As Boiko et al. point out in their publication, "The most crucial test of the tumour stem cell hypothesis is that markers or pathways restricted to tumour stem cells can be targets for curative therapies in the patient, which has not yet been done."

The following is an excerpt from the June 29, 2010 Breakthrough Technology Alert, published by Agora Financial. Agora Financial is a fully independent publisher and has no financial connections to companies listed below. Breakthrough Technology Alert’s editor is industry expert Patrick Cox. Patrick is renowned for his innovative forecasts and keeping readers “ahead of the story”.



For more information about Patrick Cox and Breakthrough Technology Alert please visit http://www.agorafinancial.com

Q&A with ISCO



International Stem Cell Corp. (OTCBB: ISCO) has also been the target of rumor campaigns. ISCO, incidentally, recently announced further positive IP news. Specifically, Advanced Cell Technology, Inc. (ACT) was just issued U.S. Patent Number 7736896 covering a method for producing retinal pigment epithelial cells. ISCO, however, had previously acquired rights to this technology from ACT, so the award solidifies their position in stem cell eye therapies.

ISCO's corneal research also got an unexpected boost last week, though it's not clear how many people know it yet. A stem cell breakthrough from Italy made quite a few headlines. The article that provoked the coverage was in the June 23 online version of The New England Journal of Medicine (NEJM). Specifically, it featured clinical research from professor Graziella Pellegrini et al. titled "Limbal Stem-Cell Therapy and Long-Term Corneal Regeneration." A helpful video by ABC News can be viewed here.



The coverage of the journal article is, however, incomplete. So let me put it in perspective.

The procedure made use of the well-established practice of extracting and cultivating limbal stem cells. Each of the patients, in effect, had stem cells removed from at least one eye. Once the adult stem cells were multiplied in the lab, they were applied to the cornea. There, they regenerated the corneal epithelium (the outermost thin layer of the cornea), restoring sight.

This is wonderful proof of the power of stem cells, but it doesn't represent a breakthrough in terms of basic science or investment possibilities. This is because the cost of extracting these surviving stem cells is very high. So is multiplying and reattaching them. The only reason the experiments were even allowed to proceed is that all the cell materials come from the subjects of the procedures. They would not have been allowed if, for example, scientists wanted to use the stem cells from one patient to treat another patient. Nor is it clear to what extent, if any, a company can patent these procedures.

On the other hand, the Italian procedures were most successful when they were combined with the implantation of replacement corneal structures. Those replacement corneas cannot be regenerated from limbal stem cells. In fact, they came from cadavers.

ISCO, however, is now able to grow them in the lab to produce cheaper, safer corneas. ISCO is involved in discussions with various companies to commercialize those parthenogenic corneal structures.

For most patients, who have enough of their own stem cells to regenerate the corneal epithelium, ISCO's corneas are all that are required to recover sight. Eventually, in fact, I suspect that ISCO will also have off-the-shelf limbal stem cells that will regenerate the corneal epithelial too. These cells would be from each of ISCO's cell bank lines. Now being established, it will include 50-100 cell lines that immune match most of the world's population. No other company has this ability to provide inexpensive stem cells for the masses.

Now allow me to debunk some of the rumors currently being spread about ISCO. Normally, as you know, I don't like to dignify these attacks, but I do make exceptions when it's important. I'm doing this, by the way, in a question-and-answer format that board chairman Ken Aldrich was kind enough to answer. The questions deal with some of the unfounded rumors circulating. If these don't concern you, feel free to skip them. Q1. Did ISCO close its financing?



A1. Yes, they did a $10 million financing, and then used $2.5 million as part of a balance sheet cleanup that removed approximately $15 million of 10% preferred stock and still left them with an additional $7.5 million in cash on the balance sheet, in addition to whatever cash was already there.

Q2. Doesn't Socius hold a lot of preferred stock that will be a future burden to ISCO?



A2. No, all of that has been retired as part of the capital restructuring announced in an 8-K filed June 11, 2010. As a result, Socius and its predecessor company, Optimus, hold no preferred shares of ISCO at all.

Q3. Is the company running out of money?



A3. Based on the monthly "burn" rate of about $550,000 for the last 15 months ($562,000 for the last quarter), the proceeds of the company's most recent financing of $7.5 million after the repayment of the outstanding preferred stock of Socius and Optimus would give the company at least 12 months of "runway," even without any additional revenues from operations, licensing or partnerships.



I could go on, but this is pretty long. Next week, I'll have more updates.

For transformational profits,

Patrick Cox

To learn more about Patrick Cox and Breakthrough Technology Alert please click here. © 2010 by Agora Financial, LLC. 808 St. Paul Street, Baltimore, MD 21202. All rights reserved. No part of this report may be reproduced by any means or for any reason without the consent of the publisher. The information contained herein is obtained from sources believed to be reliable; however, its accuracy cannot be guaranteed.

It turns out that not all the hairlike cilia projecting from the surfaces of many cells in the human body are equal--there are the myriad ones for sweeping, swimming and other functions, and then there is the until recently mysterious primary cilium.

Nearly all human cells contain these numerous microscopic projections. The more abundant variety of cilia are motile; they act like oars, paddling in coordinated waves to help propel cells through fluid, or to sweep material across cellular surfaces (as in the respiratory system, where millions of cilia lining the airways help to expel mucus, dead cells and other bodily debris). By contrast, cells also contain a single, nonmotile cilium known as the primary cilium. Its presence on cells has been known for more than a century, but many believed it was a functionless evolutionary remnant.

[More]

Cell - Biology - Cell biology - Cilium - Human body

For those of you who like stories with simple plots and tidy endings, I must confess the tale of the Human Genome Project isn't one of those. The story didn't reach its conclusion when we unveiled the first draft of the human genetic blueprint at the White House on June 26, 2000. Nor did it end on April 14, 2003, with the completion of a finished, reference sequence. [More]

Human Genome Project - White House - Biology - genetic - Francis Collins